Scientific Research & Development in European Union: Market Size, Businesses & Forecast 2026

The scientific research and development (R&D) industry in the European Union encompasses commercial, academic, and governmental activities dedicated to basic research, applied research, and experimental development across natural sciences, engineering, social sciences, and humanities. The sector serves as a primary engine for European technological innovation, industrial competitiveness, and digital transformation. According to official Eurostat figures, gross domestic expenditure on R&D (GERD) within the EU reached €403 billion in 2024, representing an R&D intensity of 2.24% of the union's gross domestic product (source: Eurostat 2024). The industry employs a growing workforce, expanding to

Industry snapshot

Key public data points

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Scientific Research & Development in European Union industry cover?

The scientific research and development industry covers systematic creative work undertaken to increase the stock of knowledge and devise new applications. Under official European statistical frameworks, the scope is divided into research and experimental development on natural sciences and engineering, alongside research on social sciences and humanities. It excludes routine engineering, quality control, market testing, and standard software development, focusing strictly on resolving scientific or technological uncertainties.

• •Classified under Section M, Division 72 of the official NACE Rev. 2 system.
• •Includes basic research aimed at acquiring new knowledge without specific applications.
• •Includes applied research directed toward specific practical objectives and experimental development leading to new products or processes.

Who operates in the industry and how is it structured?

The sector exhibits a multi-operator structure divided among private enterprises, higher education institutions, government research bodies, and private non-profit organizations. The business enterprise sector serves as the largest performer and funder of R&D across the EU, followed closely by the university and higher education framework. Geographically, market activity is highly concentrated within a few member states, notably Sweden, Belgium, Austria, and Germany, which consistently exceed the average union-wide funding baselines.

• •Business enterprises funded 56.7% of total EU R&D expenditure according to Eurostat 2023 data.
• •Government financing accounted for 30.1% of the total EU R&D funding matrix in 2023.
• •Sweden led the EU with the highest national R&D intensity at 3.57% of GDP in 2024, whereas Romania registered the lowest at 0.46% of GDP.

What drives demand in the industry?

Demand within the R&D industry is driven by corporate mandates to sustain competitive advantages, green transition imperatives, and extensive public funding schemes. Industrial sectors like pharmaceuticals, automotive, aerospace, and digital communications require continuous scientific breakthroughs to meet strict efficiency targets. Furthermore, systemic EU policy initiatives targeting regional self-reliance in semiconductors, renewable energy, and biotechnology provide structural capital deployment pipelines.

• •Corporate demand is led by high-technology manufacturing sectors attempting to accelerate time-to-market for complex products.
• •Public demand is stimulated by the European Union's institutional target to lift total regional R&D investment to 3.00% of GDP.
• •Demographic shifts and public health mandates act as structural drivers for advanced medical, clinical, and pharmacological research.

Who are the notable companies in the industry?

The competitive ecosystem consists of specialized independent research contractors, state-backed labs, and the massive internal R&D divisions of multinational corporations operating within the EU. While small and medium enterprises lead niche innovations, large public companies control substantial intellectual property portfolios and drive major clinical and industrial trials. Companies frequently engage in public-private partnerships, cross-border university consortia, and collaborative framework programs to mitigate technical risks.

• •ASML Holding N.V., headquartered in the Netherlands, commands a critical position by reinvesting billions annually into advanced lithography R&D.
• •Sanofi S.A., the France-based healthcare leader, executes extensive clinical development campaigns across multiple European hubs.
• •Siemens AG, based in Germany, anchors industrial digital twin, automation, and infrastructure hardware research platforms.
• •Evotec SE operates as a major German-headquartered drug discovery alliance and development partnership company.

What are the recent trends and outlook?

The industry is adjusting to a shifting international environment, with the EU facing rising competition from external markets like South Korea, the United States, and China. While absolute spending levels continue to tick upward, the relative share of R&D intensity has experienced minor volatility, reflecting wider macroeconomic headwinds and inflation. Human capital development remains a clear growth trend, evidenced by a steady increase in full-time research personnel across the region.

• •The number of full-time equivalent researchers in the EU expanded by 47.3% between 2014 and 2024, reaching 2.21 million.
• •The business enterprise sector employed the majority of the research workforce, accounting for 57.0% of all FTE researchers in 2024.
• •China's R&D intensity surpassed the EU's benchmark, hitting 2.36% of GDP compared to the EU's 2.28% in 2020.

How is the industry regulated?

Operations within the industry are governed by rigorous EU institutional directives, ethical frameworks, and standardized reporting mechanisms. Funding compliance is heavily dictated by financial audits linked to Horizon Europe, the union’s flagship research and innovation funding program. Intellectual property rights, clinical trial directives, data protection mandates, and standardizations across laboratory protocols ensure strict harmonization across member states.

• •Horizon Europe governs the allocation, ethical review, and open-access mandates of regional public research funding grants.
• •Regulation (EU) 2016/679 (GDPR) dictates strict compliance rules regarding data privacy in clinical, sociological, and technological trials.
• •Statistical frameworks conform to Commission Delegated Regulation (EU) 2023/137, which updates NACE structures to maintain data integrity.

Government, statistical and trade sources used for this Claight analysis.

• Eurostat R&D Expenditure Statistics 2024 ·
• Eurostat R&D Personnel Statistics 2024 ·
• European Commission NACE Classification Framework 2025